← All trials
NCT04245397
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 29, 2020
- Primary completion
- Feb 28, 2022
- Completion date
- Dec 31, 2023
- First posted
- —
- Last posted
- —
- Enrollment
- 64
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Syntrix Biosystems, Inc.Lead sponsor
- University of South FloridaOverall official - principal investigator
- National Heart, Lung, and Blood Institute (NHLBI)Collaborator
- University of South FloridaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.